↓ Skip to main content

Cochrane Database of Systematic Reviews

Artemisinin derivatives for treating uncomplicated malaria

Overview of attention for article published in Cochrane database of systematic reviews, April 1999
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

1 blog
1 policy source
1 tweeter
2 Wikipedia pages


67 Dimensions

Readers on

147 Mendeley
Artemisinin derivatives for treating uncomplicated malaria
Published in
Cochrane database of systematic reviews, April 1999
DOI 10.1002/14651858.cd000256
Pubmed ID

Heather McIntosh, Piero Olliaro


Artemisinin derivatives are a relatively new group of drugs with antimalarial properties. As resistance to other antimalarial drugs continues to increase, artemisinin drugs may be useful alternatives. The objective of this review was to assess the effects of artemisinin drugs for treating uncomplicated falciparum malaria. We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, Medline, Embase, Science Citation Index, Lilacs, African Index Medicus; conference abstracts and reference lists of relevant articles. We contacted organisations, researchers in the field and drug companies. Randomised and quasi-randomised trials of artemisinin derivatives, alone or in combination with other antimalarials, compared with standard antimalarial treatments, in adults or children with uncomplicated falciparum malaria. Only trials where treatment was given by mouth or suppository were included. Comparisons between different artemisinin derivatives and treatment regimens were also included. Eligibility and trial quality were assessed and data were extracted independently by the two reviewers. Forty-one trials involving over 5000 patients were included. Variation in study design and quality made synthesis of the data problematic. Allocation concealment was adequate in only two trials. Most data were from areas of multidrug resistant falciparum malaria in South East Asia. Compared with standard antimalarial treatments, artemisinin drugs showed fast parasite clearance and high cure rates at follow-up, provided the duration of treatment with artemisinin drugs was adequate. Combination with mefloquine improved sustained parasite clearance and was effective in multidrug resistant areas. When doses were adequate, the combination shortened the duration of treatment. We found no evidence that artemisinin drugs are more harmful than standard treatment drugs over a typical trial period of 28 days. The evidence suggests that artemisinin drugs are effective and safe for treating uncomplicated malaria. There is no evidence from randomised trials that one artemisinin derivative is better than the others. In areas where there is mefloquine resistance, combination therapy with an artemisinin derivative appears to improve sustained parasite clearance compared with either drug alone.

Twitter Demographics

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 147 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
Belgium 2 1%
Germany 1 <1%
Unknown 142 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 14%
Researcher 17 12%
Student > Ph. D. Student 14 10%
Other 12 8%
Unspecified 11 7%
Other 39 27%
Unknown 34 23%
Readers by discipline Count As %
Medicine and Dentistry 39 27%
Nursing and Health Professions 14 10%
Agricultural and Biological Sciences 12 8%
Unspecified 12 8%
Biochemistry, Genetics and Molecular Biology 6 4%
Other 27 18%
Unknown 37 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2023.
All research outputs
of 23,506,079 outputs
Outputs from Cochrane database of systematic reviews
of 12,716 outputs
Outputs of similar age
of 36,030 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 5 outputs
Altmetric has tracked 23,506,079 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,716 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.0. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 36,030 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them